Double Blind Study of Vigabatrin for the Treatment of Cocaine Dependence
NCT ID: NCT00527683
Last Updated: 2008-04-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
100 participants
INTERVENTIONAL
2007-04-30
2007-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Subjects will receive vigabatrin in escalating doses to 3 grams per day over three weeks, continued for 4 weeks and then tapered to zero over the next 2 weeks.
Vigabatrin
crystalline drug dissolved in orange juice, dosage escalates from 500 mg twice daily to 1.5 g twice daily over a 3 week period. This dose is maintained for 4 weeks and then tapered to zero over the next two weeks
Group therapy
Participants attend group sessions once a week
B
Orange juice and administration identical to Arm A.
Placebo
orange juice is administered twice daily in containers indistinguishable from the treatment arm.
Group therapy
Participants attend group sessions once a week
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vigabatrin
crystalline drug dissolved in orange juice, dosage escalates from 500 mg twice daily to 1.5 g twice daily over a 3 week period. This dose is maintained for 4 weeks and then tapered to zero over the next two weeks
Placebo
orange juice is administered twice daily in containers indistinguishable from the treatment arm.
Group therapy
Participants attend group sessions once a week
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be at least 18 years of age and no older than 55 years of age.
* Weigh more than 100 pounds.
* Have a DSM-IV diagnosis of cocaine dependence.
* Be seeking treatment for cocaine dependence.
* Have a urine sample positive for qualitative cocaine toxicology at initial screening.
* Have the ability to understand, and having understood, provide written informed consent to comply with the treatment protocol.
* Have a history and brief physical examination that demonstrate no clinically significant contraindication for participating in the study, in the judgment of the admitting physician and the Principal Investigator.
* Have normal, or, if necessary, corrected visual acuity, visual fields, and normal fundoscopy findings
Exclusion Criteria
* Meet DSM-IV criteria for current dependence on any psychoactive substance other than cocaine, alcohol, nicotine, or marijuana or physiological dependence on alcohol requiring medical detoxification.
* Have neurological or psychiatric disorders such as: psychosis, bipolar illness, major depression, organic brain disease, dementia, any disorder which would require ongoing treatment or which would make study agent compliance difficult, history of suicide attempts assessed and/or current suicidal ideation/plan.
* Have serious medical illnesses or other potentially life threatening or progressive medical illness other than addiction that may compromise subject safety or study conduct.
* Have a history of traumatic head injury.
* Be mandated by a court to obtain treatment for cocaine dependence.
* Have been treated for cocaine addiction, or abstained from cocaine use for a significant period, within the 6 months preceding screening.
* Be unable to complete the study protocol because of probable incarceration or relocation from the clinical area.
* Have AIDS (although AIDS is an exclusion criterion, a positive antibody titer to HIV is not).
* Have active syphilis that has not been treated or refuse treatment for syphilis
* Have a history of neuroleptic malignant syndrome.
* Have known or suspected hypersensitivity to vigabatrin or any other GABAergic drug.
* Have received a drug with known potential for toxicity to a major organ system within 30 days prior to study entry (e.g., isoniazid, methotrexate).
* Have participated in any experimental study within 4 weeks, or participated in any clinical trial utilizing vigabatrin.
* Be pregnant or lactating.
* Have any clinically significant abnormal laboratory value.
* Have had electroconvulsive therapy with the 3 months preceding screening.
* Have had any opiate-substitutes (methadone, LAAM, buprenorphine) within 2 months preceding screening.
* Have a history of i.v. cocaine (or other psychoactive drug) use within 2 months preceding screening.
* Have a current or past history of seizure disorder, including alcohol- or stimulant related seizure, febrile seizure, or significant family history of idiopathic seizure disorder.
* Have a visual field defect, or factor predisposing to visual field defects, including glaucoma, severe myopia, retinal disorder, cataracts, diabetes or uncontrolled hypertension.
* Have my illness, condition, and use of medications, in the opinion of the Principal Investigator and the admitting physician, which would preclude safe or successful completion of the study.
* Be using vigabatrin or any medication that could interact adversely with vigabatrin administration, based on the longest time interval of A or B below:
* A) Five half-lives of other medication or active metabolite(s), whichever is longer;
* B) Two weeks.
* Be lactose intolerant.
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Catalyst Pharmaceuticals, Inc.
INDUSTRY
NYU Langone Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
New York University School of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jonathan D Brodie, Ph.D., M.D.
Role: PRINCIPAL_INVESTIGATOR
NYU Langone Health
Emilia Figueroa, M.D.
Role: STUDY_DIRECTOR
Clinica Integral de Tratamiento Contra las Adicciones, S.A de C.V.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinica Integral de Tratamiento Contra las Adicciones SA de CV
Mexico City, Mexico City, Mexico
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Fechtner RD, Khouri AS, Figueroa E, Ramirez M, Federico M, Dewey SL, Brodie JD. Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrin: ocular safety pilot results. Arch Ophthalmol. 2006 Sep;124(9):1257-62. doi: 10.1001/archopht.124.9.1257.
Brodie JD, Figueroa E, Laska EM, Dewey SL. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse. 2005 Feb;55(2):122-5. doi: 10.1002/syn.20097.
Brodie JD, Figueroa E, Dewey SL. Treating cocaine addiction: from preclinical to clinical trial experience with gamma-vinyl GABA. Synapse. 2003 Dec 1;50(3):261-5. doi: 10.1002/syn.10278. No abstract available.
Brodie JD, Case BG, Figueroa E, Dewey SL, Robinson JA, Wanderling JA, Laska EM. Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees. Am J Psychiatry. 2009 Nov;166(11):1269-77. doi: 10.1176/appi.ajp.2009.08121811. Epub 2009 Aug 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H06-152
Identifier Type: -
Identifier Source: org_study_id